Study M856
Study name | Nie LJ 2021b |
Title | L-Carnitine and acetyl-l-carnitine: potential novel biomarkers for major depressive disorder |
Overall design | The aim of this study was to determine whether serum L-carnitine and acetyl-L-carnitine might be used as novel biomarkers for the diagnosis of major depressive disorder (MDD). Ultra-high performance liquid chromatography-tandem mass spectrometry was used to determine the concentrations of L-carnitine and acetyl-L-carnitine in the serum of healthy controls (control group, n = 89) and patients with MDD (MDD group, n = 89), and in patients who were responsive (effective group, the reduction rate of the HDRS-24 at least 50%, n = 38) and non-responsive (ineffective group, the reduction rate of HDRS-24 score < 50%, n = 17) after 2 weeks of treatment. |
Study Type | Type1; Type2; |
Data available | Unavailable |
Organism | Human; |
Categories of depression | Depressive disorder; Depression; Depression; |
Criteria for depression | Clinical diagnosis of MDD |
Sample size | 178 |
Tissue | Peripheral; Blood; Serum; |
Platform | MS-based; LC-MS: Waters Acquity ultra performance liquid chromatography with Waters Xevo TQ-S mass spectrometer (Waters, Massachusetts, USA); |
PMID | |
DOI | |
Citation | Nie LJ, Liang J, Shan F, et al. L-Carnitine and acetyl-l-carnitine: potential novel biomarkers for major depressive disorder. Front Psychiatry. 2021 Sep 30;12:671151. |
Metabolite |
